Polymers for Drug-Device Combination Products

January 28, 2019

A wide variety of polymer types are available to the DDCP developer,
and many are available on the market that meet the necessary
regulatory requirements. Careful consideration should be given to
the choice of vendor to ensure that quality and consistency are
met. The available polymers span a wide range of physical properties
and are amenable to fabrication into devices using a variety of
processes. API can be readily incorporated into these polymers using
melt-mixing or solution processing. If product developers use
contract services for development or manufacturing, it is advisable to
select partners with a breadth of experience and a solid track record.

Spotlight

Indegene

We are a technology-led healthcare solutions provider. We combine deep industry expertise with fit-for-purpose technology

OTHER WHITEPAPERS
news image

Employing Singleuse Technology to Control Frozen Bulk Drug Storage

whitePaper | September 29, 2022

New biopharmaceutical drug products that alter and even save lives can be very profitable for their developers.

Read More
news image

Association for Accessible Medicines Drug Shortages

whitePaper | June 22, 2023

Generic medicines are the backbone of the U.S. prescription drug market, supplying more than 9 out of every 10 prescriptions. And the availability of generic medicines overall is remarkably stable even during challenges such as the COVID-19 pandemic.

Read More
news image

Simcyp™ PBPK for Drug-Drug Interactions (DDI)

whitePaper | July 4, 2023

The past two decades have witnessed transformative changes in our approach to using modeling & simulation to assess and manage DDIs. Multidisciplinary innovations in mechanistic assessment of absorption, distribution, metabolism, and excretion (ADME), population pharmacology and pharmacogenetics.

Read More
news image

A pragmatic approach to developing rare disease drug

whitePaper | July 13, 2023

Most medicines in development today target diseases affecting large sections of the global population. But now we are slowly beginning to see a rise in the interest of developing ”orphan drugs,” or pharmaceutical agents intended to treat rare diseases.

Read More
news image

Seize the digital momentum

whitePaper | January 23, 2023

Investments in biopharmaceutical (biopharma) research and development (R&D) continue to fuel innovation and shape the future of health. However, this year’s analysis demonstrates that despite impressive examples of innovative products the step-change in improved productivity seen in 2021 has not continued.

Read More
news image

Pharmaceutical Sales Strategies Post-COVID-19: The Benefits of Virtual Engagement

whitePaper | April 7, 2021

In less than a week, in the face of a pandemic, the pharmaceutical sales model changed forever. In-person healthcare provider (HCP) visits came to a screeching halt and brand marketers scrambled to find ways to educate and engage these providers remotely. While the pandemic may have taken us by surprise, we should acknowledge that, even before the pandemic, pharmaceutical sales teams faced significant challenges. One solution for these challenges is to engage HCPs – virtually.

Read More

Spotlight

Indegene

We are a technology-led healthcare solutions provider. We combine deep industry expertise with fit-for-purpose technology

Events